^
Association details:
| Biomarker: | NOTCH1 deletion |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide capsule) (Androgen receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Loss of Notch1 Activity Inhibits Prostate Cancer Growth and Metastasis and Sensitizes Prostate Cancer Cells to Antiandrogen Therapies
Excerpt:
Combination of gamma secretase inhibitors with abiraterone significantly inhibited cell migration and invasion, while combination with enzalutamide reversed enzalutamide-induced migration and invasion. These collective findings suggest loss of NOTCH1 delays growth of CRPC and inhibits metastasis, and inhibition of Notch1 activation in conjunction with second-generation antiandrogen therapies could delay growth and progression of prostate cancer.
Secondary therapy:
abiraterone acetate
DOI:
10.1158/1535-7163.MCT-18-0804
